Stock listing
E8LA Stock Price, News, Filings & Events — Geovax Labs, Inc.
Selected listing: E8LA · SWB · EUR · DE
This page tracks Geovax Labs, Inc.'s E8LA:SWB listing on SWB in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following E8LA:SWB. E8LA:SWB is the stock-level entry point for investors researching Geovax Labs, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Geovax Labs, Inc. (ticker: GOVX) is a public company based in the United States, focusing on the development of innovative vaccines and immunotherapies. With a market capitalization of approximately $3.81 million, Geovax is engaged in advancing its product pipeline to address various infectious diseases and cancers. The company aims to leverage its proprietary technologies to create effective solutions for global health challenges.

- Ticker
- E8LA:SWB
- Asset type
- Stock
- Market cap
- $4.8M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- SWB
- Currency
- EUR
Geovax Labs, Inc. E8LA:SWB stock context
This page tracks Geovax Labs, Inc.'s E8LA:SWB listing on SWB in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following E8LA:SWB. E8LA:SWB is the stock-level entry point for investors researching Geovax Labs, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Geovax Labs, Inc. (ticker: GOVX) is a public company based in the United States, focusing on the development of innovative vaccines and immunotherapies. With a market capitalization of approximately $3.81 million, Geovax is engaged in advancing its product pipeline to address various infectious diseases and cancers. The company aims to leverage its proprietary technologies to create effective solutions for global health challenges.
Latest news from Geovax Labs, Inc.
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
August 25, 2026
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
August 20, 2026
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Bas...
August 3, 2026
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update
July 27, 2026
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
July 21, 2026
Research Geovax Labs, Inc.
Geovax Labs, Inc. investor report
Review AI stock analysis and investor report context for E8LA:SWB.
Geovax Labs, Inc. company profile
View the public company page for Geovax Labs, Inc. on 6ix.
Geovax Labs, Inc. news
Read company news and market updates connected to Geovax Labs, Inc..
Geovax Labs, Inc. investor events
Find investor webinars, events, and replay context for Geovax Labs, Inc..